Midatech Pharma Plc Margen de beneficio
¿Qué es el Margen de beneficio de Midatech Pharma Plc?
El Margen de beneficio de Midatech Pharma Plc es -1,095.85%
¿Cuál es la definición de Margen de beneficio?
El margen de ganancia es una medida de la rentabilidad. La misma se calcula al encontrar la ganancia neta como un porcentaje de los ingresos.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Margen de beneficio de compañías en Sector Health Care en LSE en comparadas con Midatech Pharma Plc
¿Qué hace Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Empresas con margen de beneficio similar a Midatech Pharma Plc
- Tempo Australia tiene Margen de beneficio de -1,112.63%
- Immutep tiene Margen de beneficio de -1,112.50%
- Rollatainers tiene Margen de beneficio de -1,108.02%
- Asia Resources tiene Margen de beneficio de -1,107.88%
- RedFlow tiene Margen de beneficio de -1,101.61%
- Cellectis SA tiene Margen de beneficio de -1,099.67%
- Midatech Pharma Plc tiene Margen de beneficio de -1,095.85%
- Phunware Inc tiene Margen de beneficio de -1,092.40%
- Mesoblast tiene Margen de beneficio de -1,091.87%
- Geomega Resources tiene Margen de beneficio de -1,090.91%
- Sunwah Kingsway Capital tiene Margen de beneficio de -1,090.28%
- Arcimoto tiene Margen de beneficio de -1,084.39%
- Neovasc tiene Margen de beneficio de -1,081.36%